man standing in the street smiling - Jeremy Hand

Pancreatic Cancer UK appoints new trustees to support bold five-year strategy

We are delighted to announce that three new trustees have joined our board as we launch our bold new strategy to double survival for the deadliest common cancer by 2028. Anne Tutt, Dr Iain Frame and Jeremy Hand, a pancreatic cancer survivor, have been recruited to support our ambition to find the breakthroughs which will provide hope – and save lives.

Each will add decades of professional expertise and their personal experience of pancreatic cancer:

A woman smiling at the camera - Anne Tutt

Anne Tutt is a qualified Chartered Accountant with more than 25 years of Board-level experience across a range of sectors, including healthcare for UK and multinational groups. She is currently Vice Chair of Oxford University Hospitals NHS Trust. Anne knows the devastating impact of pancreatic cancer having lost her husband to the disease.

man smiling at camera with white background Dr Iain Frame

Dr Iain Frame has a proven track record in innovation, organisational strategy development and delivery, having worked with a number of medical research charities. He is keen to help improve the research environment and support researchers to do the work needed to enable the benefits from research to get to patients more effectively.

man standing in the street smiling - Jeremy Hand

Jeremy Hand has built a successful career supporting leadership teams and growing businesses. As well as founding and growing several of his own private equity companies, he brings huge experience at the intersect of strategy, successful execution and impact. He is also a pancreatic cancer survivor and brings vital lived experience of the disease to the Board.

 

“We were clear about the skills needed within the board to support Diana and her team in successfully executing the exciting and ambitious 5 year strategy. Anne, Iain and Jeremy clearly bring a wealth of domain expertise which will help Pancreatic Cancer UK scale for impact. I am thrilled to have their knowledge, passion and personalities join the team."

Eleanor Phillips, Chair of Pancreatic Cancer UK

In stark contrast to other forms of cancer, survival rates for pancreatic cancer have barely improved in 50 years. Tragically, just 7 per cent of people diagnosed with the disease in the UK will live for five years, making it the deadliest common cancer. By 2028 our charity aims to double survival rates and ensure that everyone affected is able to access the information, care, and support they need to have a better quality of life.

Anne Tutt said: “I lost my husband to pancreatic cancer, also a close business colleague. I am so happy to be joining the Board of Pancreatic Cancer UK, giving me the opportunity to make a contribution to fighting this dreadful disease and supporting those people and their families suffering from it.“

Dr Iain Frame said: “I have long admired the work the charity does for those affected by pancreatic cancer and its newly launched strategy is bold, ambitious and importantly, achievable. The enthusiasm of the Pancreatic Cancer UK team to deliver the successful outcomes needed is infectious and I am looking forward to bringing my expertise and enthusiasm to the Board and wider team to support them in their endeavours.”

Jeremy Hand said “Five years ago, I was diagnosed with pancreatic cancer.  Today, I am completely clear and proud to be joining the board of trustees at Pancreatic Cancer UK to help tackle this most fatal of all cancers.”

We are the only charity taking on the disease across all fronts: funding world-class research into earlier diagnosis and more effective treatment, campaigning for change, and by providing vital information and support to patients and their families.

Diana Jupp CEO of Pancreatic Cancer UK said: “We are delighted to welcome our new trustees and are very excited about the expertise and guidance each will add to the Board at such an important time for the charity. Pancreatic cancer is the toughest of cancer challenges but in the last five years we have seen more progress than in the previous five decades. It’s time to step up the pace and bring forward the day when everyone survives this deadly disease.”